Mar. 6 at 2:06 PM
$RVVTF My Overall OpinionRVVTF (Revive Therapeutics) is a classic high-risk, speculative penny stock in the biotech sector, with intriguing but early-stage assets in Bucillamine and psilocybin that could yield upside if clinical milestones are hit—especially with FDA fast-tracks or partnerships for medical countermeasures. The refocus on core programs and cost reductions show prudent management, and recent news (e.g., stroke publication, nerve agent study) could spark interest in a niche market for rare disorders and emergencies. The low market cap (~
$8M) prices in significant downside, making it potentially attractive for aggressive investors betting on breakthroughs.That said, it's not for the faint-hearted: no revenue, mounting losses, negative equity, and constant dilution scream caution. Liquidity is razor-thin, and without fresh capital or positive trial data by mid-2026, bankruptcy or reverse splits are real possibilities. I'd view it as a lottery ticket—monitor for updates on
